Wedbush keeps an Outperform rating on Tyra Biosciences with a $27 price target, saying the company recently provided several updates on the development status of its selective FGFR3 inhibitor, TYRA-300, and TYRA-200, targeting FGFR2-altered cancers. The firm notes the company will present Phase 1 SURF301 data at a scientific congress in 2024. Further, SURF301 has cleared the planned doses for a randomized Phase 2 trial of TYRA-300 in pediatric achondroplasia, for which the company expects to submit a new drug application in the second half of 2024, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TYRA:
- Tyra Biosciences doses first patient with TYRA-200
- Tyra Biosciences downgraded to Neutral from Buy at BofA
- Tyra Biosciences price target lowered to $19 from $20 at H.C. Wainwright
- Tyra Biosciences reports Q3 EPS (49c), consensus (35c)
- Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights
